Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

Six months after entering talks with U.S. private equity firm Clayton, Dubilier & Rice (CD&R), Sanofi has closed a deal to ...

Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...

Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp, a healthcare ...

Journalist with 30 years in news writing for CNN, KLAS-TV, WCMH-TV, Newsweek, Mediaite, and RawStory. Author of the award-nominated non-fiction book, "Stealing Sisi's Star," now a serial podcast ...

In March, Sanofi penned a $1.6 billion agreement with Dren Bio for a CD20-directed antibody aimed at B-cell non-Hodgkin lymphoma. Sanofi—which co-markets the anti-inflammatory blockbuster ...

Sanofi just last month agreed to pay $600 million to Dren Bio for a drug it hopes can “reset” the immune system. Earendil uses artificial intelligence to streamline drug discovery and speed up ...

Sanofi just last month agreed to pay $600 million to Dren Bio for a drug it hopes can “reset” the immune system. Earendil uses artificial intelligence to streamline drug discovery and speed up ...

JavaScript is disabled in your web browser or browser is too old to support JavaScript. Today almost all web pages contain JavaScript, a scripting programming language that runs on visitor's web ...

April 16, 2025--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird" or "the Company") today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd.